Impact of macrolide therapy in critically ill patients with acute respiratory failure: a desirability of outcome ranking analysis to investigate the OUTCOMEREA database

  • Stéphanie Pons
  • Jean-François Timsit
  • Stéphane Ruckly
  • Carole Schwebel
  • Laurent Papazian
  • Elie Azoulay
  • Jean Reignier
  • Lara ZafraniEmail author



We thank all the patients who participated in the database and all the members of the OUTCOMEREA Study Group (ESM 2). No financial support has been received to conduct this study.

Compliance with ethical standards

Conflicts of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Ethical standard statement

These retrospective analyses of a prospective observational study were exempt from approval per the institutional review board or local ethics committee. In accordance with French legislation on non-interventional studies, the need for signed informed consent from the participants was waived. However, the patients and their next of kin were asked whether they were willing to participate in the database.

Supplementary material

134_2019_5586_MOESM1_ESM.doc (84 kb)
ESM 1: Desirability of outcome ranking (DOOR).
134_2019_5586_MOESM2_ESM.doc (210 kb)
ESM 2: Members of the OUTCOMEREA Study Group.
134_2019_5586_MOESM3_ESM.docx (133 kb)
Supplemental Figure 1: Flowchart.
134_2019_5586_MOESM4_ESM.doc (217 kb)
Supplemental Table E1: Demographical and clinical characteristics of patients with acute respiratory failure depending on the administration or not of a macrolide therapy within 3 days after intensive care unit admission.
134_2019_5586_MOESM5_ESM.docx (15 kb)
Supplemental Table E2: Multivariate logistic regression of confounding factors associated with macrolide therapy administration within 3 days following intensive care unit admission and included in the inverse probability of treatment weighting model.
134_2019_5586_MOESM6_ESM.docx (72 kb)
Supplemental Table E3: Unweighted and IPTW-adjusted probabilities of a better outcome in the macrolides group compared to the non-macrolide group.


  1. 1.
    Cigana C, Assael BM, Melotti P (2007) Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother 51:975–981. CrossRefGoogle Scholar
  2. 2.
    Kawamura K, Ichikado K, Takaki M et al (2016) Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis. SpringerPlus 5:1193. CrossRefGoogle Scholar
  3. 3.
    Walkey AJ, Wiener RS (2012) Macrolide antibiotics and survival in patients with acute lung injury. Chest 141:1153–1159. CrossRefGoogle Scholar
  4. 4.
    Giamarellos-Bourboulis EJ, Pechère J-C, Routsi C et al (2008) Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 46:1157–1164. CrossRefGoogle Scholar
  5. 5.
    Giacobbe DR, Signori A, Tumbarello M et al (2018) Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia. Eur J Clin Microbiol Infect Dis. Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Stéphanie Pons
    • 1
  • Jean-François Timsit
    • 2
    • 3
  • Stéphane Ruckly
    • 3
  • Carole Schwebel
    • 4
  • Laurent Papazian
    • 5
  • Elie Azoulay
    • 6
  • Jean Reignier
    • 7
  • Lara Zafrani
    • 1
    • 6
    Email author
  1. 1.INSERM U976, Saint-Louis University HospitalParisFrance
  2. 2.Infectious and Medical Intensive Care UnitBichat Claude-Bernard University HospitalParisFrance
  3. 3.INSERM IAME, U1137, Team DesCIDParisFrance
  4. 4.Polyvalent Intensive Care UnitGrenoble University HospitalGrenobleFrance
  5. 5.Respiratory and Infectious Diseases Intensive Care UnitNorth University HospitalMarseilleFrance
  6. 6.Medical Intensive Care UnitSaint-Louis HospitalParisFrance
  7. 7.Medical Intensive Care UnitNantes University Hospital CenterNantesFrance

Personalised recommendations